{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:23:29Z","timestamp":1769851409131,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12288-017-0798-8","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T13:57:18Z","timestamp":1488549438000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting"],"prefix":"10.1007","volume":"33","author":[{"given":"Rajiv","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhushan","family":"Asthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Chilaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velu","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"798_CR1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/bmt.2010.118","volume":"46","author":"INM Micallef","year":"2011","unstructured":"Micallef INM, Ho AD et al (2011) Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 46:350\u2013355","journal-title":"Bone Marrow Transplant"},{"key":"798_CR2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbmt.2011.10.003","volume":"18","author":"F Malard","year":"2012","unstructured":"Malard F, Kreoger N et al (2012) Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 18:309\u2013329","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"798_CR3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","volume":"15","author":"U Popat","year":"2009","unstructured":"Popat U, Saliba R et al (2009) Impairment of filgastrim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718\u2013723","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2014.196","volume":"50","author":"I S\u00e1nchez-Ortega","year":"2015","unstructured":"S\u00e1nchez-Ortega I, Querol S et al (2015) Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant 50:34\u201339","journal-title":"Bone Marrow Transplant"},{"key":"798_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20:295\u2013308","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/trf.12813","volume":"55","author":"J Cheng","year":"2015","unstructured":"Cheng J, Schmitt M et al (2015) Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion 55:275\u2013283","journal-title":"Transfusion"},{"key":"798_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2010.224","volume":"25","author":"M Mohty","year":"2011","unstructured":"Mohty M, Duarte RF, Croockewit S, H\u00fcbel K, Kvalheim G, Russell N (2011) The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25:1\u20136","journal-title":"Leukemia"},{"key":"798_CR8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1537-2995.2011.03349.x","volume":"52","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Lemoni RM (2012) Preemptive use of plerixafor in difficult-to-mobilizepatients: an emerging concept. Transfusion 52:906\u2013914","journal-title":"Transfusion"},{"key":"798_CR9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","volume":"18","author":"AP Nademanee","year":"2012","unstructured":"Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ et al (2012) Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34+ cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 18:1564\u20131572","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1537-2995.2012.03744.x","volume":"53","author":"F Lefr\u00e8re","year":"2013","unstructured":"Lefr\u00e8re F, Mauge L, R\u00e9a D, Ribell JA, Dal Cortivo L, Brignier AC et al (2013) A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizers: impact on the timing of the apheresis procedure. Transfusion 53:564\u2013569","journal-title":"Transfusion"},{"key":"798_CR11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045\u20131056","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","volume":"20","author":"A Alegre","year":"1997","unstructured":"Alegre A, Tomas JF, Martinez-Chamorro C et al (1997) Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211\u2013217","journal-title":"Bone Marrow Transplant"},{"key":"798_CR13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.1998.16.4.1547","volume":"16","author":"KR Desikan","year":"1998","unstructured":"Desikan KR, Barlogie B, Jagannath S et al (1998) Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547\u20131553","journal-title":"J Clin Oncol"},{"key":"798_CR14","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.1995.13.10.2547","volume":"13","author":"W Bensinger","year":"1995","unstructured":"Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547\u20132555","journal-title":"J Clin Oncol"},{"key":"798_CR15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.V98.7.2059","volume":"98","author":"U Narayanasami","year":"2001","unstructured":"Narayanasami U, Kanteti R, Morelli J et al (2001) Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98:2059\u20132064","journal-title":"Blood"},{"key":"798_CR16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10428190009065829","volume":"39","author":"C Dazzi","year":"2000","unstructured":"Dazzi C, Cariello A, Rosti G et al (2000) Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin\u2019s lymphoma? Leuk Lymphoma 39:301\u2013310","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 2","key":"798_CR17","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/sj.bmt.1701670","volume":"23","author":"JA Glaspy","year":"1999","unstructured":"Glaspy JA (1999) Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 23(Suppl 2):S21\u2013S27","journal-title":"Bone Marrow Transplant"},{"key":"798_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1701941","volume":"24","author":"R Kanteti","year":"1999","unstructured":"Kanteti R, Miller K, McCann J et al (1999) Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease: a clinical and molecular analysis. Bone Marrow Transplant 24:473\u2013481","journal-title":"Bone Marrow Transplant"},{"key":"798_CR19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045\u20131056","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","volume":"20","author":"A Alegre","year":"1997","unstructured":"Alegre A, Tomas JF, Martinez-Chamorro C et al (1997) Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211\u2013217","journal-title":"Bone Marrow Transplant"},{"key":"798_CR21","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1182\/blood.V118.21.4048.4048","volume":"118","author":"NJ Chao","year":"2011","unstructured":"Chao NJ, Grima DT, Carrum G et al (2011) Chemo-mobilization provides superior mobilization and collection in autologous stem cell transplants but with less predictability and at a higher cost. ASH Annual Meeting Abstracts. Blood 118:4048","journal-title":"Blood"},{"key":"798_CR22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.1998.16.4.1547","volume":"16","author":"KR Desikan","year":"1998","unstructured":"Desikan KR, Barlogie B, Jagannath S et al (1998) Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547\u20131553","journal-title":"J Clin Oncol"},{"key":"798_CR23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1046\/j.1365-2141.2001.02498.x","volume":"112","author":"KR Desikan","year":"2001","unstructured":"Desikan KR, Tricot G, Munshi NC et al (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 112:242\u2013247","journal-title":"Br J Haematol"},{"key":"798_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","volume":"6","author":"D Dingli","year":"2006","unstructured":"Dingli D, Nowakowski GS, Dispenzieri A et al (2006) Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 6:384\u2013388","journal-title":"Clin Lymphoma Myeloma"},{"key":"798_CR25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbmt.2013.05.008","volume":"19","author":"Paul Shaughnessy","year":"2013","unstructured":"Shaughnessy Paul, Chao Nelson et al (2013) Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transplant 19:1301\u20131309","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"798_CR26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2014-03-544759","volume":"124","author":"Morie A Gertz","year":"2014","unstructured":"Gertz Morie A, Dingl David (2014) How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 124(6):882\u2013890","journal-title":"Blood"},{"key":"798_CR27","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","volume":"22","author":"A Mazumder","year":"2008","unstructured":"Mazumder A, Kaufman J, Niesvizky R et al (2008) Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 22:1280\u20131281 (author reply 1281-1282)","journal-title":"Leukemia"},{"key":"798_CR28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.thj.6200061","volume":"1","author":"IN Micallef","year":"2000","unstructured":"Micallef IN, Apostolidis J, Rohatiner AZ et al (2000) Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-hodgkin\u2019s lymphoma. Hematol J 1:367\u2013373","journal-title":"Hematol J"},{"issue":"Suppl 2","key":"798_CR29","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/sj.bmt.1701671","volume":"23","author":"PJ Stiff","year":"1999","unstructured":"Stiff PJ (1999) Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 23(Suppl 2):S29\u2013S33","journal-title":"Bone Marrow Transplant"},{"key":"798_CR30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajh.21400","volume":"84","author":"C Hosing","year":"2009","unstructured":"Hosing C, Saliba RM, Ahlawat S et al (2009) Poor hematopoietic stem cell mobilizers: a single-institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84:335\u2013337","journal-title":"Am J Hematol"},{"key":"798_CR31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","volume":"16","author":"P Wuchter","year":"2010","unstructured":"Wuchter P, Ran D, Bruckner T et al (2010) Poor mobilization of hematopoietic stem cellsddefinitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 16:490\u2013499","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR32","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood.V83.12.3787.3787","volume":"83","author":"R Haas","year":"1994","unstructured":"Haas R, Mohle R, Fruhauf S et al (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787\u20133794","journal-title":"Blood"},{"key":"798_CR33","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar S, Dispenzieri A, Lacy MQ et al (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21:2035\u20132042","journal-title":"Leukemia"},{"key":"798_CR34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","volume":"25","author":"F Cavallo","year":"2011","unstructured":"Cavallo F, Bringhen S, Milone G et al (2011) Stem cell mobilization in patients with newly diagnosed multiple myeloma after Lenalidomide induction therapy. Leukemia 25:1627\u20131631","journal-title":"Leukemia"},{"key":"798_CR35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","volume":"103","author":"O Tournilhac","year":"2004","unstructured":"Tournilhac O, Cazin B, Lepr\u00e8tre S et al (2004) Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 103:363\u2013365","journal-title":"Blood"},{"key":"798_CR36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/bmt.2011.109","volume":"47","author":"J Waterman","year":"2011","unstructured":"Waterman J, Rybicki L, Bolwell B et al (2011) Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 47:488\u2013493","journal-title":"Bone Marrow Transplant"},{"key":"798_CR37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.bmt.1704184","volume":"32","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Kuittinen T, Nousiainen T (2003) Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-hodgkin\u2019s lymphoma? Bone Marrow Transplant 32:569\u2013573","journal-title":"Bone Marrow Transplant"},{"key":"798_CR38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbmt.2013.11.003","volume":"20","author":"LJ Costa","year":"2014","unstructured":"Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP et al (2014) Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients:implications for risk-stratification. Biol Blood Marrow Transplant 20:222\u2013228","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR39","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ et al (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-hodgkin\u2019s lymphoma. J Clin Oncol 27:4767\u20134773","journal-title":"J Clin Oncol"},{"issue":"2","key":"798_CR40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3324\/haematol.2012.071456","volume":"98","author":"N Russell","year":"2013","unstructured":"Russell N, Douglas K et al (2013) Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Hematologica 98(2):172\u2013178","journal-title":"Hematologica"},{"key":"798_CR41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","volume":"22","author":"H Paripati","year":"2008","unstructured":"Paripati H, Stewart AK, Cabou S et al (2008) Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22:1282\u20131284","journal-title":"Leukemia"},{"key":"798_CR42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.22038","volume":"86","author":"GW Basak","year":"2011","unstructured":"Basak GW, Jaksic O, Koristek Z et al (2011) Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 86:550\u2013553","journal-title":"Am J Hematol"},{"key":"798_CR43","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","volume":"141","author":"R Popat","year":"2008","unstructured":"Popat R, Oakervee HE, Hallam S et al (2008) Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 141:512\u2013516","journal-title":"Br J Haematol"},{"key":"798_CR44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12185-008-0218-9","volume":"89","author":"S Lu","year":"2009","unstructured":"Lu S, Wang J, Xu X et al (2009) Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol 89:34\u201338","journal-title":"Int J Hematol"},{"key":"798_CR45","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/cncr.25143","volume":"116","author":"JL Kaufman","year":"2010","unstructured":"Kaufman JL, Nooka A, Vrana M et al (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer 116:3143\u20133151","journal-title":"Cancer"},{"key":"798_CR46","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","volume":"27","author":"AJ Jakubowiak","year":"2009","unstructured":"Jakubowiak AJ, Kendall T, Al-Zoubi A et al (2009) Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 27:5015\u20135022","journal-title":"J Clin Oncol"},{"key":"798_CR47","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/10428190903452826","volume":"51","author":"A Corso","year":"2010","unstructured":"Corso A, Barbarano L, Mangiacavalli S et al (2010) Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leuk Lymphoma 51:236\u2013242","journal-title":"Leuk Lymphoma"},{"key":"798_CR48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/leu.2010.82","volume":"24","author":"P Moreau","year":"2010","unstructured":"Moreau P, Hulin C, Marit G et al (2010) Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 24:1233\u20131235","journal-title":"Leukemia"},{"issue":"e255","key":"798_CR49","first-page":"1","volume":"4","author":"RE Clark","year":"2014","unstructured":"Clark RE, Bell J et al (2014) Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilization, and is effective even in heavily pretreated patients. Blood Cancer J 4(e255):1\u20136","journal-title":"Blood Cancer J"},{"key":"798_CR50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/bmt.2011.133","volume":"47","author":"S Abhyankar","year":"2011","unstructured":"Abhyankar S, Dejarnette S, Aljitawi O et al (2011) A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 47:483\u2013487","journal-title":"Bone Marrow Transplant"},{"key":"798_CR51","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood.V118.21.4389.4389","volume":"118","author":"J LaPorte","year":"2011","unstructured":"LaPorte J, Solomon SR, Bashey A et al (2011) An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation. ASH Annual Meeting Abstracts. Blood 118:4389","journal-title":"Blood"},{"issue":"Suppl 2","key":"798_CR52","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/j.bbmt.2009.12.141","volume":"16","author":"IN Micallef","year":"2010","unstructured":"Micallef IN, Inwards DJ, Dispenzieri A et al (2010) A risk-adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 16(Suppl 2):S197\u2013S198","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","volume":"46","author":"LJ Costa","year":"2011","unstructured":"Costa LJ, Alexander ET, Hogan KR et al (2011) Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 46:64\u201369","journal-title":"Bone Marrow Transplant"},{"key":"798_CR54","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1537-2995.2011.03136.x","volume":"51","author":"J Li","year":"2011","unstructured":"Li J, Hamilton E, Vaughn L et al (2011) Effectiveness and cost analysis of \u201cjustin- time\u201d salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 51:2175\u20132182","journal-title":"Transfusion"},{"key":"798_CR55","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2012.74","volume":"47","author":"AI Chen","year":"2012","unstructured":"Chen AI, Bains T, Murray S et al (2012) Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 47:1526\u20131529","journal-title":"Bone Marrow Transplant"},{"key":"798_CR56","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","volume":"18","author":"AP Nademanee","year":"2012","unstructured":"Nademanee AP, DiPersio JF et al (2012) Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34 hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34 cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 18:1564\u20131572","journal-title":"Biol Blood Marrow Transplant"},{"key":"798_CR57","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720\u20135726","journal-title":"Blood"},{"key":"798_CR58","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/15258160050196812","volume":"9","author":"KR Meehan","year":"2000","unstructured":"Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K (2000) Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res 9:767\u2013771","journal-title":"J Hematother Stem Cell Res"},{"key":"798_CR59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1537-2995.2011.03206.x","volume":"52","author":"P Vishnu","year":"2012","unstructured":"Vishnu P, Roy V, Paulsen A, Zubair AC (2012) Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 52:55\u201362","journal-title":"Transfusion"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-017-0798-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-017-0798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-017-0798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T09:51:53Z","timestamp":1601718713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-017-0798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s12288-017-0798-8","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}